Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab'

Acta Oncol. 2021 Feb 20:1-3. doi: 10.1080/0284186X.2021.1889028. Online ahead of print.NO ABSTRACTPMID:33612057 | DOI:10.1080/0284186X.2021.1889028

Source: Acta Oncologica - February 22, 2021 Category: Cancer & Oncology Authors: Mehmet Zahid Kocak Source Type: research